Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13812901 | 0.89 | CALCA (0.57) | CALCAKMT2AEGLN1SMN1; SMN2RPS6KB1 | |
| SCHEMBL6504246 | 0.87 | CALCA (0.60) | CALCAKMT2AEGLN1SMN1; SMN2RPS6KB1 | |
| SCHEMBL6490436 | 0.86 | CALCA (0.62) | CALCAKMT2AEGLN1SMN1; SMN2RPS6KB1 | |
| SCHEMBL4065349 | 0.86 | KMT2A (0.48) | CALCAKMT2AEGLN1SMN1; SMN2RPS6KB1 | |
| SCHEMBL4060740 | 0.85 | CALCA (0.61) | CALCAKMT2AEGLN1SMN1; SMN2RPS6KB1 | |
| SCHEMBL7263637 | 0.85 | ADORA2A (0.45) | CALCAKMT2AEGLN1 | |
| SCHEMBL4059851 | 0.84 | CALCA (0.63) | CALCAKMT2AEGLN1RPS6KB1ERCC1 | |
| SCHEMBL7101920 | 0.84 | CALCA (0.60) | CALCAKMT2AEGLN1SMN1; SMN2RPS6KB1 | |
| SCHEMBL4067905 | 0.83 | KMT2A (0.61) | CALCAKMT2AEGLN1RPS6KB1ERCC1 | |
| SCHEMBL4067912 | 0.83 | KMT2A (0.61) | CALCAKMT2AEGLN1RPS6KB1ERCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326865-B1 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20050176718-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | ANTHONY NEVILLE J (US) | 2005-08-11 | — | — | US | disclosed |
| US-6921759-B2 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1326865-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030055071-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. | 2003-03-20 | — | — | US | disclosed |
| WO-2002030930-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030931-A2 | AZA- AND POLYAZA-NAPHTHALENYL CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055071-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | POLI, DUT, NAAA | CALCA 3366/4885KMT2A 61/4885AKT3 2814/4885 |
| US-20050176718-A1 | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors | POLI, DUT, NAAA | CALCA 3366/4885KMT2A 61/4885AKT3 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.